Release Date: July 28, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- IQVIA Holdings Inc IQV delivered outstanding second quarter results with revenue, adjusted EBITDA, and adjusted diluted earnings per share all exceeding the high end of guidance.
- Organic growth accelerated to 6% year-over-year, three times the rate from the previous year.
- R&D Solutions segment showed strong performance with nearly 9% revenue growth and a 19% increase in net new bookings year-over-year.
- Commercial Solutions segment experienced organic revenue growth of 5%, with analytics and consulting growing at the highest rate since 2022.
- AI-enabled capabilities are enhancing IQVIA's offerings, leading to improved study design, accelerated timelines, and reduced operational risk in clinical trials.
Negative Points
- The company faces potential risks and uncertainties associated with forward-looking statements, as discussed in their SEC filings.
- Foreign exchange impacts have been a headwind, reducing the tailwind effect in the revenue guidance.
- Pass-through growth, which comes with no profit, created an 80 basis point headwind to margins.
- The acquisition of Charles River assets, while expanding capabilities, has lower margins, impacting overall margin performance.
- Despite strong bookings, the long-cycle nature of the R&D business means that current bookings are more indicative of future performance rather than immediate revenue growth.
Q & A Highlights
Q: Were there any notable call-outs within the bookings for this quarter, such as chunky awards or pass-through mix?
A: Ari Bousbib, Chairman and CEO, stated that the quarter was exceptionally strong with no unusual or abnormal elements in the numbers. The strength was broad-based across the board, with pass-throughs and cancellations within the normal range. FSO was very strong, and there was a good mix of large, mid, and EBP bookings.
Q: Can you elaborate on the potential increase in outsourcing penetration, particularly with large and mid-sized pharma customers?
A: Ari Bousbib explained that the EBP segment is fully outsourced, and IQVIA is the largest CRO provider to this segment. Large pharma clients are increasingly using AI in discovery, which is expected to increase demand for CRO services. Some large pharma clients predict doubling their study portfolios, leading to increased outsourcing due to the need for additional capacity and expertise.
Q: How does IQVIA plan to develop its AI solutions over time, and where are the incremental dollars being invested?
A: Ari Bousbib highlighted that IQVIA has been investing in AI for years, focusing on proprietary healthcare data, deep domain knowledge, and regulatory compliance. IQVIA has 294 AI agents deployed across 90 use cases, and partnerships with top pharma companies to co-develop AI solutions. The company continues to prioritize AI as a key investment area.
Q: What factors contribute to IQVIA's ability to displace other CROs in competitive processes?
A: Ari Bousbib noted that large pharma companies have renegotiated partnerships, and IQVIA has increased the number and scope of these relationships. In competitive RFPs, discussions focus on delivery timelines, capabilities, technology, site networks, therapeutic expertise, and AI capabilities, rather than price.
Q: Can you provide more details on the operational drivers behind the faster-than-expected improvement in EBITDA margins?
A: Michael Fedock, CFO, explained that operational and productivity programs, including AI, drove about 90 basis points of operational margin expansion. Non-operational items like FX had zero impact, while pass-through growth created an 80 basis point headwind. The company also benefits from leverage off its fixed cost base with stronger revenues.
Q: How does the guidance raise for organic revenue growth reflect market improvements versus better execution and win rates?
A: Ari Bousbib stated that the improving market environment, reflected in strong RFP flows and funding growth in the EBP segment, contributes to the guidance raise. Additionally, IQVIA's improved win rates, driven by capabilities and strong position in the EBP segment, also play a significant role.
Q: How is the revenue guidance increase allocated between improving demand in R&DS and Commercial Solutions?
A: Michael Fedock mentioned that the guidance reflects acceleration in growth for both segments. The R&DS segment's long-cycle nature means current bookings are more indicative of future growth, while Commercial Solutions is seeing immediate acceleration.
Q: Can you clarify the impact of acquisitions on revenue growth and segment contributions?
A: Michael Fedock clarified that acquisitions contributed about 2.5% to revenue growth, with the impact typically being two-thirds in Commercial Solutions and one-third in R&DS. The acquisition of Charles River assets added approximately $75 million to $80 million in revenue.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
